EarningsCLH posted solid Q2 adjusted EBITDA, modestly above consensus, and narrowed the 2025 guidance, at the midpoint in line with Street expectations.
Financial PerformanceCLH delivered a solid second quarter, reiterated full-year guidance, and made encouraging commentary on the overall health of the business.
ValuationWith Kimball ramping, SKSS largely de-risked, valuation attractive and reshoring and PFAS providing longer-term tailwinds, the stock is viewed favorably.